SCHEMBL7201819

SCHEMBL7201819

COC(=O)N(C(=O)[C@@H](N)C(C)C)C(=O)[C@@H]1CCCN1[C@H](C(=O)c1nn(Cc2ccsc2)c(=O)o1)C(C)C

nearest known ligand 0.32

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.30
ALDH1A1 P00352 1/20 0.30
KMT2A Q03164 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7205718 0.91 FKBP1A (0.33)
SCHEMBL7199835 0.89 OPRM1 (0.32) ALDH1A1
SCHEMBL7202834 0.89 USP2 (0.34) ALDH1A1
SCHEMBL7202365 0.86
SCHEMBL7201784 0.85 ALDH1A1 (0.34) MEN1ALDH1A1KMT2A
SCHEMBL7201125 0.82
SCHEMBL7201093 0.81 DPP4 (0.30)
SCHEMBL7202223 0.80
SCHEMBL7198867 0.80 ABHD16A (0.34)
SCHEMBL7205294 0.80 F10 (0.31) MEN1ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030087831-A1 1,3,4-Oxadiazolin-2-one derivatives and drugs containing these derivatives as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2003-05-08 US claimed
EP-1234834-A1 1,3,4-OXADIAZOLIN-2-ONE DERIVATIVES AND DRUGS CONTAINING THESE DERIVATIVES AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2002-08-28 EP claimed
US-20030087831-A1 1,3,4-Oxadiazolin-2-one derivatives and drugs containing these derivatives as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2003-05-08 US disclosed
EP-1234834-A1 1,3,4-OXADIAZOLIN-2-ONE DERIVATIVES AND DRUGS CONTAINING THESE DERIVATIVES AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2002-08-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030087831-A1 1,3,4-Oxadiazolin-2-one derivatives and drugs containing these derivatives as the active ingredient SERPINB1, ELANE, MMP8 MEN1 3608/4885ALDH1A1 597/4885KMT2A 4863/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.